BioNJ’s Beyond Value Frameworks Workshop
Continuing the Conversation…Seeking Solutions
Thursday, October 11, 2018 | Amicus Therapeutics, Cranbury, NJ
BioNJ will host its Third Annual Beyond Value Frameworks Workshop on October 11 at Amicus Therapeutics bringing together Patients, industry, payers, academia and government to discuss and contribute to the development of new platforms that will provide Patients with access to the right medicines at the right time at affordable out-of-pocket costs.
Designed for individuals responsible for pricing, policy, market access and reimbursement, attendees will learn how to become engaged and influential regarding framework decisions, to gather tools and information to be better able to challenge value assessments, to measure Patient-centered value and to learn about new analytic computational platforms that can demonstrate and calculate drug value.
An Interactive Program with Industry Thought Leaders
|8:00 a.m. – 8:45 a.m.||Registration and Networking Breakfast|
|8:45 a.m. – 9:00 a.m.||Welcome and Opening Remarks
Debbie Hart, President & CEO, BioNJ
|9:00 a.m. – 9:45 a.m.||A Fireside Chat with Andrew Pecora, M.D., Chief Innovations Officer, Hackensack Meridian Health
“Don’t Do Too Much, Don’t Do Too Little… Do the Right Thing Each Time”
|9:45 a.m. – 10:45 a.m.||Patient-Centered Access: Real Life Examples
Don Sawyer, Vice President, U.S. Market Access, Celgene
Leigh Anne Leas, Vice President and U.S. Country Head, Public Policy, Novartis
Ellen Miller-Sonet, Chief Strategy and Policy Officer CancerCare
Moderator: Kevin Rigby, General Manager, Rigby ConsultingCost-sharing barriers are a leading reason that patients do not take medicines as prescribed — resulting in billions of dollars of unnecessary expenses to the healthcare system and ultimately negatively impacting successful medical treatment. As a result, biopharma companies are beginning to proactively work with healthcare payers on specially designed programs ensuring that patients have access to the therapies they need without deductibles, co-pays and co-insurance. During this interactive session, you’ll hear real-life examples and case studies on what’s worked, what hasn’t and lessons learned.
|10:45 a.m. – 11:00 a.m.||Networking Break|
|11:00 a.m. – 12:00 p.m.||Identifying Barriers to Adoption: Formulating a Multi-Voice Approach
Bob Gold, CEO, GoMo Health
Steven Peskin, M.D., Executive Medical Director, Population Management, Horizon Blue Cross Blue Shield of New Jersey
Terry Wilcox, Co-Founder & Executive Director, Patients Rising and Patients Rising NOW
Moderator: Robert Goldberg, Ph.D., Vice President & Founder, Center for Medicine in the Public Interest
While “personalized medicine” offers great promise for improving patient outcomes, it has had little impact on healthcare delivery. In particular, there are barriers limiting the development and use of patient-level evidence to measure and predict outcomes. As a result, public policy and coverage decisions are still being made on a population-wide basis. Our panel will discuss what those barriers are and how biotech companies, patients, providers and payors can overcome them.
|12:00 p.m. – 12:15 p.m.||Closing Remarks|
|12:15 p.m. – 1:00 p.m.||Interactive Working Lunch: Enabling Prospective, Personalized Medicine|
Join in this important conversation. Your voice matters. If you are responsible for pricing, policy, market access or reimbursement, you need to be here!
Visit www.BioNJ.org/vomi for BioNJ’s Value of Medical Innovation Toolbox featuring reference tools, resources and communication pieces on the value of medical innovation, the importance of Patient access and the true cost and affordability of life-saving medicines move forward.
Click here for a Sneak Peak … Continuing the Conversation!
Featuring Dr. Andrew Pecora, Chief Innovations Officer at Hackensack Meridian Health, our first segment in BioNJ’s “Value of Medical Innovation Thought Leadership” video series showcases the innovative work being led by Dr. Pecora to help Patients throughout the world, including precision medicine, real-world evidence and paying for outcomes.
Thank You to Our Host Sponsor:
Thank You to Our Sponsor: